RT Journal Article
SR Electronic
T1 A practical approach to the cholesterol guidelines and ASCVD prevention
JF Cleveland Clinic Journal of Medicine
JO Cleve Clin J Med
FD Cleveland Clinic
SP 15
OP 20
DO 10.3949/ccjm.87.s1.02
VO 87
IS 5 suppl 1
A1 Cho, Leslie
YR 2020
UL http://www.ccjm.org/content/87/5_suppl_1/15.abstract
AB Lifestyle factors remain the bedrock of atherosclerotic cardiovascular disease (ASCVD) prevention. Statins remain the first-line therapy for primary and secondary prevention of ASCVD. Physicians are encouraged to discuss the risks and benefits of statins with patients before beginning therapy. Nonstatins and proprotein convertase subtilisin-kexin type 9 inhibitors are recommended for secondary prevention in patients with clinical ASCVD. For patients at intermediate risk of ASCVD, new risk-enhancing factors, including chronic inflammatory conditions and ethnicity, should be considered to better risk stratify these patients.